GeneHealth - Your precision medicine

Isolated Growth Hormone Deficiency Type Iii

Disease Details

Family Health Simplified

Buy Membership

Description: Isolated Growth Hormone Deficiency Type III (IGHD Type III) is a genetic disorder characterized by insufficient production of growth hormone, often resulting in short stature and potential immune system dysfunction due to accompanying immunoglobulin deficiency.
Type: Isolated Growth Hormone Deficiency Type III (IGHD Type III) is a genetic disorder primarily classified as an endocrine condition. It is characterized by insufficient production of growth hormone, leading to various growth abnormalities.

Type of genetic transmission: IGHD Type III is typically inherited in an autosomal dominant manner. This means that only one copy of the altered gene inherited from either parent can cause the disorder.
Signs And Symptoms: Isolated Growth Hormone Deficiency Type III (IGHD Type III) is a condition characterized primarily by a deficiency in growth hormone. Signs and symptoms of IGHD Type III may include:

- Short stature: Children with IGHD Type III are often significantly shorter than their peers.
- Delayed growth and development: Slower growth rates and delayed puberty.
- Hypoglycemia: Low blood sugar, especially in infants.
- Increased body fat: Particularly around the abdomen.
- Reduced muscle mass and strength.
- Low energy levels and fatigue.
- Potential delayed or absence of sexual maturation during adolescence.

IGHD Type III specifically can also be associated with immune system abnormalities, due to mutations in the BTK gene, which affects the differentiation and function of B-cells in the immune system.

Typical laboratory findings may include low levels of growth hormone in the blood and poor response to growth hormone stimulation tests. Diagnosis often involves genetic testing and assessment of pituitary function.

Treatment generally involves regular administration of recombinant human growth hormone to stimulate growth and address deficiency symptoms.
Prognosis: Isolated Growth Hormone Deficiency Type III (IGHD III) is typically characterized by short stature due to insufficient production of growth hormone. Prognosis for individuals with IGHD III can vary. With appropriate and timely growth hormone therapy, many affected individuals can achieve near-normal adult height. Treatment also often improves other symptoms associated with growth hormone deficiency. However, long-term management and regular monitoring are crucial for optimizing outcomes and addressing any potential complications.
Onset: Isolated Growth Hormone Deficiency Type III typically manifests in early childhood. The primary symptom is abnormally short stature that becomes more evident as the child grows. Additional symptoms may include delayed bone age, a youthful facial appearance, and other developmental delays. Early diagnosis and treatment can help manage the condition and improve growth outcomes.
Prevalence: The prevalence of Isolated Growth Hormone Deficiency Type III (IGHD Type III) is not well-documented in medical literature, making it difficult to provide a specific number. It is considered a rare genetic disorder.
Epidemiology: Epidemiology: Isolated Growth Hormone Deficiency Type III is a rare genetic disorder characterized by the insufficient production of growth hormone. The exact prevalence is not well-documented due to its rarity, but it is generally considered an uncommon condition. It has been reported in various populations without a clear ethnic or geographic predilection. Early diagnosis and treatment are crucial for managing growth and development in affected individuals.
Intractability: Isolated Growth Hormone Deficiency Type III (IGHD Type III) is not considered intractable. It can be treated with growth hormone replacement therapy, which typically involves regular injections of recombinant human growth hormone. Early diagnosis and consistent treatment can help manage symptoms and promote normal growth and development in affected individuals. However, the response to treatment can vary, and ongoing medical management may be required.
Disease Severity: Isolated Growth Hormone Deficiency Type III: The severity of this condition can vary, but it typically involves short stature due to inadequate production of growth hormone. Other symptoms may include delayed bone age, reduced muscle mass, and hypoglycemia in infants. Some individuals may also experience a normal eventual height with appropriate treatment.
Healthcare Professionals: Disease Ontology ID - DOID:0060875
Pathophysiology: Isolated Growth Hormone Deficiency Type III (IGHD Type III) is a rare genetic disorder characterized by the insufficient secretion of growth hormone (GH) due to defects in the GH1 gene. The pathophysiology primarily involves mutations in the GH1 gene, which is responsible for encoding growth hormone. These genetic mutations lead to reduced or absent synthesis of growth hormone, impairing normal growth and development. As a result, individuals with IGHD Type III often present with short stature and may have delayed bone age, but generally have normal body proportions. The disruption in GH secretion affects the stimulation of growth and the overall metabolic regulation dependent on this hormone.
Carrier Status: For isolated growth hormone deficiency type III, the carrier status is an individual who carries one copy of the pathogenic variant of the gene responsible for the condition but does not typically exhibit symptoms.
Mechanism: Isolated Growth Hormone Deficiency Type III (IGHD type III) is a genetic disorder characterized by a deficiency in growth hormone production. Here's a detailed look at its mechanism and molecular mechanisms:

**Mechanism:**
- **Problem in Hormone Production**: IGHD type III is marked by the inadequate production of growth hormone (GH) from the pituitary gland, which is crucial for normal growth and metabolism.
- **Autoimmune Deficiency**: Occasionally, the deficiency may arise due to immune system-related damage to GH-producing cells in the pituitary.

**Molecular Mechanisms:**
- **Genetic Mutations**: This condition is often caused by mutations in specific genes that are involved in the development and function of the pituitary gland. Notably, mutations in the GH1 gene, which encodes growth hormone, are commonly implicated.
- **Signal Transduction Pathways**: Mutations can disrupt the signaling pathways required for proper GH synthesis and secretion.
- **Transcription Factors**: Defective transcription factors (like PIT-1 or PROP1) may result in the impaired expression of genes essential for the production and release of GH, leading to deficiencies.

Understanding these molecular mechanisms provides insight into the genetic and biochemical bases of IGHD type III, which is essential for diagnosis and developing targeted therapies.
Treatment: Isolated Growth Hormone Deficiency Type III (IGHD Type III) is a genetic disorder that affects growth hormone production. Treatment typically involves:

1. **Growth Hormone Replacement Therapy**: Regular injections of synthetic growth hormone to promote normal growth and development.
2. **Monitoring**: Regular follow-up with a healthcare provider to monitor growth, hormone levels, and response to therapy.
3. **Management of Associated Conditions**: Addressing any other health issues that may arise due to the deficiency.

NAN: Not applicable or no additional information provided.
Compassionate Use Treatment: For Isolated Growth Hormone Deficiency Type III (IGHD Type III), compassionate use treatments and off-label or experimental therapies could include:

1. **Recombinant Human Growth Hormone (rhGH)**: While rhGH is the standard treatment for growth hormone deficiencies, use in IGHD Type III, particularly if the condition is severe or unresponsive to standard doses, might sometimes be approached in experimental settings or via compassionate use protocols.

2. **IGF-1 Therapy**: Insulin-like Growth Factor 1 (IGF-1) therapy might be considered experimentally in cases where patients have poor response to rhGH. It's important in managing growth disorders that are resistant to standard treatments.

3. **Gene Therapy**: This is an emerging experimental approach and involves correcting the genetic defects responsible for IGHD Type III. It's not widely available and is typically limited to clinical trials.

4. **Clinical Trials**: Participation in clinical trials exploring new drugs or biological treatments targeting the pathways involved in growth hormone production and regulation.

5. **Off-label Use of Medications**: Certain medications that influence the endocrine system, while not specifically approved for IGHD Type III, might be used off-label based on the physician's discretion and available evidence.

These treatments would typically be considered on a case-by-case basis, often when conventional therapies have failed, and always under strict medical supervision.
Lifestyle Recommendations: Lifestyle recommendations for isolated growth hormone deficiency type III can include:

1. **Healthy Diet**: Ensure a balanced diet rich in essential nutrients to support overall health and development.
2. **Regular Exercise**: Engage in regular physical activity appropriate for their age to promote muscle strength and overall fitness.
3. **Regular Monitoring**: Frequent medical check-ups to monitor growth progress and adjust treatment plans as necessary.
4. **Mental Health Support**: Provide emotional and psychological support to manage any self-esteem or social concerns.
5. **Therapeutic Interventions**: Physical and occupational therapy might be beneficial to address any motor skill delays.
6. **Sleep Hygiene**: Encourage proper sleep routines to promote growth and overall well-being.
7. **Education and Awareness**: Educate family and caregivers about the condition to help create a supportive environment.

These measures can help individuals manage their condition more effectively alongside any medical treatments prescribed by their healthcare provider.
Medication: Isolated Growth Hormone Deficiency Type III (IGHD Type III) is treated with recombinant human growth hormone (rhGH) therapy. This treatment involves regular injections of synthetic growth hormone to stimulate growth and development. The specific dosages and treatment plans are tailored to the individual patient's needs and are usually overseen by a healthcare professional specializing in endocrinology. Note: "nan" might indicate "not applicable" if no specific medication is noted under that context.
Repurposable Drugs: Isolated Growth Hormone Deficiency Type III (IGHD Type III) is a condition characterized by the insufficient production of growth hormone, leading to various growth abnormalities. It is specifically associated with mutations in the GHRHR gene.

As of now, the primary treatment for IGHD Type III typically involves growth hormone replacement therapy (GHRT). This comprises the administration of recombinant human growth hormone (rhGH) to supplement the deficient hormone levels.

There are no widely recognized repurposable drugs specifically for IGHD Type III, apart from the standard treatment involving GHRT. Research continues to explore new therapeutic options, but no alternative repurposable drugs have emerged as standard care.

For the latest and most tailored treatment options, consulting with a healthcare professional or endocrinologist is recommended.
Metabolites: For isolated growth hormone deficiency type III, there are no specific metabolites directly associated with this condition.
Nutraceuticals: There are no specific nutraceuticals that are widely recognized as standard treatment for isolated growth hormone deficiency type III (IGHD type III). Management typically involves growth hormone replacement therapy under the guidance of an endocrinologist. Nutraceuticals may be considered on a case-by-case basis to support overall health, but they are not a substitute for medical treatment. Please consult a healthcare provider for personalized advice.
Peptides: Isolated Growth Hormone Deficiency Type III (IGHD Type III) is a genetic disorder affecting the production of growth hormone (GH), leading to short stature and other growth-related issues. The condition is inherited in an autosomal dominant, autosomal recessive, or X-linked recessive manner.

**Peptides**: Growth hormone itself is a peptide hormone produced by the pituitary gland. In IGHD Type III, the production or secretion of this hormone is impaired. Treatment commonly involves recombinant human growth hormone (rhGH), a synthetic peptide that mimics natural GH, which is administered to stimulate growth and development.

**Nan**: The term "nan" could refer to various contexts, but within the scope of IGHD Type III, it might be a typographical error or an abbreviation that is not standard within this medical context. If it was intended to signify "not a number" (NaN), it would not be applicable here. Further clarification would be needed to address this correctly.

Please provide more context if "nan" was meant to refer to something specific.